William Blair Analysts Raise Earnings Estimates for NMRA

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Analysts at William Blair lifted their Q1 2025 earnings estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Monday, March 3rd. William Blair analyst M. Minter now anticipates that the company will post earnings of ($0.37) per share for the quarter, up from their previous estimate of ($0.47). William Blair has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.85) EPS, FY2028 earnings at ($1.48) EPS and FY2029 earnings at ($0.26) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

Other analysts have also issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. HC Wainwright lowered their target price on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Bank of America decreased their target price on Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Neumora Therapeutics Trading Up 1.4 %

Shares of NASDAQ NMRA opened at $1.43 on Thursday. Neumora Therapeutics has a twelve month low of $1.35 and a twelve month high of $21.00. The stock has a 50 day moving average of $2.83 and a two-hundred day moving average of $8.76. The stock has a market cap of $231.03 million, a P/E ratio of -0.76 and a beta of 2.59.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently modified their holdings of NMRA. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics in the 4th quarter valued at $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $64,000. Quantbot Technologies LP acquired a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $92,000. PEAK6 LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $117,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $135,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.